Authors
Latest:
Rare disease patient supportRare diseases are hard to treat; supporting the patient can be even more challenging
Latest:
Extend Sampling Programs With Telemarketing and Direct MailA biopharma marketer uses direct mail and a call center to access hard-to-reach physicians
Latest:
Biopharma cold-chain market forecastMore biologic-based therapies translates into more cold chain activity. As yet, new cellular and genetic therapies are a minute part of the overall market.
Latest:
A case study in differing approaches to reimbursement approval in Europe and the USLooking at 'cost' and 'value' under different evaluation processes
Latest:
Recent US Supreme Court decisions narrow life-sciences patentability claimsIndustry response may be to keep more innovations as trade secrets
Latest:
Six Steps to Driving Patient Support Program EnrollmentAlthough there is no ‘one size fits all’ solution, the process is influenced by factors such as lifestyle stage, competitive outlook, and market constraints.
Latest:
Multi-Indication Drug Branding in Today’s Pharmaceutical IndustryAs drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
Latest:
Key Elements for Success in Pharma M&A IntegrationHow can buyers maximize the value of their acquisitions?
Latest:
GS1 standards are vital for pharma serialization‘Future proof’ your implementation by adhering to industry standards
Latest:
Online personal data will be a boon for patient supportSpecialty-pharma support providers have a potential benefit in behavioral targeting insights
Latest:
First physicians, now patients: Risk avoidance in patient support programsA look into the growing compliance risks associated with patient services
Latest:
Pragmatic randomized clinical trials: Real-world evidence made for payers and regulatorsA complement to the classic randomized clinical trial may benefit drug commercialization
Latest:
The Battle for Control of Specialty DrugsSpecialty distributors, specialty pharmacies and healthcare providers are all competing for a dominant position in drug delivery and reimbursement
Latest:
Analyzing drug-pricing mechanismsPricing systems in US drug supply chain have many limitations; an analytics-based method might avoid some of them
Latest:
Generic Manufacturers Gain Another Advantage in Disputing Drug PatentsFDA sets a precedent for granting generic approvals even when initial litigation goes against the generic manufacturer
Latest:
Make your CRM vendor a true partner to your sales teamToday's cloud-based, fast-evolving CRM systems call for a closer partnership between vendor and client
Latest:
Protecting pharmaceutical exclusivity: Avoiding the hidden dangers of double patentingMultiple patents contribute to a robust portfolio; however, each patent that issues can potentially become a landmine to another
Latest:
Manufacturers can support the ICD-10 transitionHealthcare's conversion to a new coding system can affect drug prescribing. Here's what you need to know
Latest:
Monetizing Intellectual Property: Royalties, Revenues and Alternative Sources of CapitalInvestment funds have developed an interest in trading capital for royalties on drug commercializations
Latest:
Active packaging protects oral solid formulationsNew technologies offer improved shelf life for moisture- and oxygen-sensitive oral solids
Latest:
The Truth Behind IDNs: Is It Who You Know, or What You Know?Connecting with buying influences in integrated delivery networks is a challenge
Latest:
The Drive to Develop New Commercial ModelsIndustry’s coming challenges will force dramatic change on how products are brought to market and businesses are sustained. Industry leaders have already started the process
Latest:
REMS Drives Manufacturer-Specialty Pharmacy RelationshipsSpecialty pharmacies are competing to position themselves as the best partners for manufacturers dealing with high-touch, high-risk products
Latest:
Pharma in China--calculated risk gone wrongDoing business in China is undergoing important changes
